Benign prostatic hyperplasia (BPH) is one of the most common diseases in aging men. It can cause bothersome lower urinary tract symptoms that affect quality of life by interfering with normal daily activities and sleep patterns. BPH typically occurs in men older than 40 years of age. By the time they reach 60 years of age, 50% of men have BPH. The etiology of BPH is only partly understood. Whereas prostate enlargement is universal in men with functioning testes, it is arrested bilateral orchiectomy. Although androgens, and particularly testosterone, are not direct causes of BPH their presence is critical to the normal growth and development of the prostate as well as BPH. Within the prostate the testosterone is converted dihydrotestosterone (DHT) under the influence of an enzyme called 5a-reductase, DHT is the locally active form of testosterone that supports prostate growth and development throughout life, and the prostate remains sensitive to androgen production throughout life to maintain both prostate size and function. As the man ages and prostate enlargement occurs , 5areductase and DHT levels remains similar to those seen in younger men, but never evidence has shown that the balance between two forms of this enzyme may be compromised , contributing to prostatic enlargement. Additional factors associated with BPH include a defect in local substances that regulate the programmed cellular death (apoptosis) common to many tissues in the body, including the skin and gastrointestinal tract .Imbalances of local growth factors, local inflammation, and genetic factors are also thought to influence the risk of BPH and the timing of its onset. Multiple possible risk for BPH has been studied. For example dietary factors have been examined and lycopene in cooked tomatoes, green and yellow vegetables, and other elements of a traditional Japanese diet appear to provide some protection against BPH. Obesity (particularly increased abdominal girth) may increase the risk for BPH.The effect of DM on BPH appears to be minimal. Physical activity has been shown to exert a protective effect against prostatic enlargement, possibly because of its indirect effects on obesity. Smoking has been hypothesized to exert protective effect on BPH because it reduces serum testosterone levels , but epidemiologic studies have shown that it has only slight effect on BPH risk compared with the well-documented and severe adverse health risk associated with cigarette use. Heavy alcohol use and cirrhosis of the liver impede prostate enlargement. Frequent use of a-adrenergic agonists commonly found in the over-the-counter cold medications or diet pills increased the severity of bothersome LUTS associated with BPH and the risk for acute urinary retention. Hypertension, heart disease, diabetes, and a western diet (high in animal fat and protein and refined carbohydrates, low in fiber) are risk factors for BPH. Histologic evidence of prostate enlargement alone does not constitute clinically relevant problem. Instead, the clinical disorders associated with BPH occur when this enlargements obstructs the urinary outlet, leading to bothersome LUTS, an increased risk of urinary tract infection , and compromised your upper urinary tract function. Two processes produce this obstruction: hyperplasia and hypertrophy. Hyperplasia originates in the glandular (stomal) cells near the urethra – transitional zone.On the microscope level, prostatic hyperplasia is nodular, but the effect on palpation is symmetrically enlarge gland free from palpable nodes characteristics of prostate cancer. Obstruction occurs when hyperplasia narrows the lumen of the segment of the urethra coursing through the prostate. Obstruction also occurs when the prostate encroaches to the bladders neck, reducing its ability to funnel in response to micturation, and when growth of the so-called median lobe of the prostate it extends to the prostatic urethra. BPH is also influenced by the prostatic capsule (connective tissue covering the gland); inward increasing the size of the prostate rather than the severity of urethral compression and urinary obstruction.Hypertropphy of the smooth muscle of the prostate also contributes to urethral obstruction via both active and passive forces. Hyperplasia of the prostate is accompanied by hypertrophy of the smooth muscle of the gland. Smooth muscle hypertrophy exacerbates urinary obstruction by increasing muscle tone at the bladder neck and in the proximal (prostatic) urethra mechanically by adding to the tissue constricting the urethral lumen. BPH may or not lead to lower urinary tract symptoms; if symptoms occur, they may range from mild to severe. Severity of symptoms increases with age, and half of men with BPH report having moderate to severe symptoms. Obstructive and irritative symptoms may include urinary frequency, urgency, nocturia, hesitancy in starting urination, decreased and intermittent force of stream and the sensation of incomplete bladder emptying, abdominal straining with urination, a decrease in the volume and force of the urinary stream, dribbling (urine dribbles out after urination), and complications of acute urinary retention (more than 60mL of urine remaining in the bladder after urination), and recurrent UTIs. Ultimately, chronic urinary retention and large residual volumes can lead to azotemia (accumulation of nitrogenous waste products) and renal failure. The health history focuses on the urinary tract, previous surgical procedures, general health issues, family history of prostate disease, and fitness for possible surgery. A patient voiding diary is used ro record voiding frequency and urine volume. A DRE often reveals a large, rubbery, and nontender prostate gland. A urinalysis to screen for hematuria and UTI is recommended. A PSA level is obtained if the patient has at least a 10-year life expectancy and for whom knowledge of the presence of prostate cancer would change knowledge of the presence of prostate cancer would change management. The AUA symptom Index or international Prostate symptom score (IPPS) can be used to assess the severity of symptoms (AUA, 2006). Other diagnostic test may include urinary flow-rate recording and the measurement of postvoid residual (PVR) urine. If invasive therapy is considered, urodynamic studies, urethrocystoscopy, and ultrasound may be performed. Cardiac status and respiratory unction are assessed because a high percentage of patients with BPH have cardiac or respiratory disorders because of their age. The goals of medical management of BPH are to improve quality of life, improve urine flow, relieve obstruction, prevent disease progression, and minimize complications. Treatment depends on the severity of the obstruction, and the patient’s condition. If patient is admitted on an emergency basis because he is unable to void, he is immediately catheterized. The ordinary catheter may be too soft and pliable to advance through the urethra into the bladder. In such cases, a thin wire (stylet) is introduced (by urologist) into the catheter to prevent the catheter from collapsing when it encounters resistance. A metal catheter may be used if obstruction is severe. An incision into the bladder (a suprapubic cystostomy) may be needed to provide urinary drainage. Pharmacologic treatment for BPH includes use of alpha-adrenergic blockers and 5-alpha-reductase inhibitors (AUA,2006). Alpha-adrenergic blockers, which include alfuzosin (uroxatral), terazosin (hytrin), doxazosin (Cardura), and tamsulosin, relax the smooth muscle of the bladder of the neck and prostate. This improves urine flow and relieves symptoms of BPH. Side effects include dizziness, headache, asthenia/fatigue, postural hypotension, rhinitis, and sexual dysfunction. Another method of treatment includes hormonal manipulation with antiandrogen agents. The alpha-alpha-reductase inhibitors, finasteride (proscar) and dutasteride (Avodart), are used to prevent the conversion of testosterone to DHT and decrease prostate size. Side effects include decreased libido, ejaculatory dysfunction, erectile dysfunction, gynecomastia (breast enlargement), and flushing. Combination therapy (doxazosin and finasteride) has decreased symptoms and decreased clinical progression of BPH. Use of pythotherapeutic agents and other dietary supplements (serenoa repens and pygeum africanum are not recommended, although they are commonly used. They may function by interfering with the conversion of testosterone to DHT. In addition, S. repens may directly block the ability of DHt to stimulate prostate cell growth. These agents should not be used with finasteride, dutasteride, or estrogencontaining medications. Other treatment options include minimaly invasive procedures and resection of prostate gland. Several forms of minimally invasive therapy may be used to treat BPH. Transurethral microwave heat treatment (TUMT) involves the application of heat to prostatic tissue highenergy TUMT devices and low-energy devices are available. A transurethral probe is inserted into the urethra, and microwaves are directed to the prostate tissue. The targeted tissue becomes necrotic and sloughs. To minimize damage to the urethra and decrease the discomfort from the procedure, some systems have a water-cooling apparatus. Other minimally invasive treatment options include (transurethral needle ablation by radiofrequency energy and the UroLume stent. TUNA uses low-level radiofrewuencies delivered by the thin needles placed in the prostate gland to produce localized heat that destroys prostate tissue while sparing other tissues. The body then resorbs the dead tissue. Prostatics stents are associated with significant complications; therefore. They are used only for patients with urinary retention and in patients who are poor surgical risks. Surgical resection of the prostate gland is another option for patients with moderate to severe lower urinary tract symptoms of BPH and for those with acute urinary retention or other complications. The specific surgical approach and the energy source are based on the surgeon’s experience, the size of the prostate gland, the presence of other medical disorders, and the patient’s preference. If surgery is to be performed, all clotting effects must be corrected and medications for anticoagulation withheld because bleeding is complication of prostate surgery. Transurethral resection of the prostate (TURP) remains benchmark for surgical treatment of BPH. It involves the surgical removal of the inner portion of the prostate through an endoscope inserted through the urethra; no external skin incision is made. It can be performed with ultrasound guidance. The treated tissue either vaporizes or becomes necrotic and sloughs. The procedure is performed in the outpatient setting and usually results in less postoperative bleeding than a traditional surgical prostatectomy. Other surgical options for BPH include transurethral incision of the prostate (TUIP), transurethral electrovaporization, laser therapy, and open prostatectomy. TUIP is an outpatient procedure used to treat smaller prostates. One or two cuts are made in the prostate and prostate capsule to reduce constriction of the urethra and decrease resistance to flow urine out of the bladder, and no tissue is removed. Open prostatectomy involves the surgical removal of the inner portion of the prostate via a suprapubic, retropubic, or perineal approach for large prostate glands. Prostatectomy may also be performed laparoscopically or by a robotassisted laparoscopy. Several tests help to confirm Benign Prostatic Hyperplasia (BPH) diagnosis: · Excretory urography may indicate urinary tract obstruction, hydronephrosis, calculi or tumors, and filling and emptying defects in the bladder. · Elevated blood urea nitrogen · Serum creatinine levels suggest impaired renal function. · Urinalysis and urine culture · Cystourethroscopy · Intravenous pyelography (IVP) · Transrectal prostatic ultrasound (TRUS) · A prostate-specific antigen test may be performed to rule out prostatic cancer. Nursing diagnosis nursing care plans for Benign Prostatic Hyperplasia (BPH) Urinary retention (acute or chronic) related to bladder obstruction Common nursing diagnosis found in patient with Benign Prostatic Hyperplasia (BPH) · Acute pain · Fear/Anxiety [specify level] · Impaired urinary elimination · deficient Knowledge regarding condition,prognosis, treatment, self-care, and discharge needs · Risk for infection · Risk for injury · Sexual dysfunction · Urinary retention Urinary Retention Care (NIC) Independent Encourage patient to void every 2–4 hr and when urge is May minimize urinary retention/over distension of the noted. bladder. Ask patient about stress incontinence when moving, High urethral pressure inhibits bladder emptying or can sneezing, coughing, laughing, lifting objects. inhibit voiding until abdominal pressure increases enough for urine to be involuntarily lost. Observe urinary stream, noting size and force. Useful in evaluating degree of obstruction and choice of intervention. Have patient document time and amount of each voiding. Urinary retention increases pressure within the ureters and Note diminished urinary output. Recommend sitz bath as indicated. Promotes muscle relaxation, decreases edema, and may enhance voiding effort. Collaborative Administer medications as indicated: Androgen inhibitors, e.g., finasteride (Proscar); Reduces the size of the prostate and decreases symptoms if taken long-term; however, side effects such as decreased libido and ejaculatory dysfunction may influence patient’s choice for long-term use. Alpha-adrenergic antagonists, e.g., tamsulosin Studies indicate that these drugs may be as effective as (Flomax), prazosin (Minipress), terazosin (Hytrin), Proscar for outflow obstruction and may have fewer side doxazosin mesylate (Cardura); effects in regard to sexual function. Antispasmodics, e.g., oxybutynin (Ditropan); Relieves bladder spasms related to irritation by the catheter. http://nursinglectures.blogspot.com FREE NURSING Prepare for surgical intervention, e.g.: Inflation of a balloon-tipped catheter within the obstructed Balloon urethroplasty/transurethral dilation of the area stretches the urethra and displaces prostatic tissue, prostatic urethra; thus improving urinary flow. A procedure of almost equivalent efficacy to transurethral Transurethral incision of the prostate (TUIP); resection of the prostate (TURP) used for prostates with estimated resected tissue weight of 30 g or less. It may be performed instead of balloon dilation with better outcomes. Procedure can be done in ambulatory or short-stay settings. Note: Open prostate resection procedures (TURP) are typically performed on patients with very large prostate glands. Heating the central portion of the prostate by the insertion Transurethral microwave thermotherapy (TUMT). of a heating element through the urethra destroys prostate cells. Treatment is usually completed in a one-time procedure carried out in the physician’s office. Recommend bedrest as indicated. Bedrest may be needed initially during acute retention phase; however, early ambulation can help restore normal voiding patterns and relieve colicky pain. Provide comfort measures, e.g., back rub, helping patient Promotes relaxation, refocuses attention, and may enhance assume position of comfort. Suggest use of coping abilities. relaxation/deep-breathing exercises, diversional activities. Encourage use of sitz baths, warm soaks to perineum. Promotes muscle relaxation. Collaborative Insert catheter and attach to straight drainage as indicated. Draining bladder reduces bladder tension and irritability. Instruct in prostatic massage. Aids in evacuation of ducts of gland to relieve congestion/inflammation. Contraindicated if infection is present. Administer medications as indicated: Narcotics, e.g., meperidine (Demerol); Given to relieve severe pain, provide physical and mental relaxation. Antibacterials, e.g., methenamine hippurate (Hiprex); Reduces bacteria present in urinary tract and those introduced by drainage system. Antispasmodics and bladder sedatives, e.g., flavoxate Relieves bladder irritability. (Urispas), oxybutynin (Ditropan). Encourage increased oral intake based on individual needs. Patient may have restricted oral intake in an attempt to control urinary symptoms, reducing homeostatic reserves Monitor BP, pulse. Evaluate capillary refill and oral and increasing risk of dehydration/hypovolemia. mucous membranes. Enables early detection of and intervention for systemic Promote bedrest with head elevated. hypovolemia. Decreases cardiac workload, facilitating circulatory Collaborative homeostasis. Monitor electrolyte levels, especially sodium. As fluid is pulled from extracellular spaces, sodium may Administer IV fluids (hypertonic saline) as needed. follow the shift, causing hyponatremia. Replaces fluid and sodium losses to prevent/correct hypovolemia following outpatient procedures. Anxiety Reduction (NIC) Independent Be available to patient. Establish trusting relationship with Demonstrates concern and willingness to help. Encourages patient/SO. discussion of sensitive subjects. Provide information about specific procedures and tests Helps patient understand purpose of what is being done, and what to expect afterward, e.g., catheter, bloody urine, and reduces concerns associated with the unknown, bladder irritation. Be aware of how much information including fear of cancer. However, overload of information patient wants. is not helpful and may increase anxiety. Maintain matter-of-fact attitude in doing procedures/ Communicates acceptance and eases patient’s dealing with patient. Protect patient’s privacy. embarrassment. Encourage patient/SO to verbalize concerns and feelings. Defines the problem, providing opportunity to answer questions, clarify misconceptions, and problem-solve solutions. Reinforce previous information patient has been given. Allows patient to deal with reality and strengthens trust in caregivers and information presented. Recommend avoiding spicy foods, coffee, alcohol, long May cause prostatic irritation with resulting congestion. automobile rides, rapid intake of fluids (particularly Sudden increase in urinary flow can cause bladder alcohol). distension and loss of bladder tone, resulting in episodes of acute urinary retention. Address sexual concerns, e.g., during acute episodes of Sexual activity can increase pain during acute episodes but prostatitis, intercourse is avoided, but may be helpful in may serve as massaging agent in presence of chronic treatment of chronic condition. disease. Note: Medications such as finasteride (Proscar) are known to interfere with libido and erections. Alternatives include terazosin (Hytrin), doxazosin mesylate (Cardura), and tamsulosin (Flomax), which do not affect testosterone levels. Disease Process (NIC) Independent Provide information about basic sexual anatomy. Having information about anatomy involved helps patient Encourage questions and promote a dialogue about understand the implications of proposed treatments concerns. because they might affect sexual performance. Review signs/symptoms requiring medical evaluation, e.g., Prompt interventions may prevent more serious cloudy, odorous urine; diminished urinary output, inability complications. to void; presence of fever/chills. Discuss necessity of notifying other healthcare providers of Reduces risk of inappropriate therapy, e.g., use of diagnosis. decongestants, anticholinergics, and antidepressants, which can increase urinary retention and may precipitate an acute episode. Reinforce importance of medical follow-up for at least 6 Recurrence of hypertrophy and/or infection (caused by mo to 1 yr, including rectal examination, urinalysis. same or different organisms) is not uncommon and requires changes in therapeutic regimen to prevent serious complications. POTENTIAL CONSIDERATIONS following acute hospitalization (dependent on patient’s age, physical condition/presence of complications, personal resources, and life responsibilities) Urinary Retention [acute/chronic]—urethral obstruction, decompensation of detrusor musculature, loss of bladder tone. Infection, risk for—urinary stasis, invasive procedure (periodic catheterization). Common nursing diagnosis found in patient with Benign Prostatic Hyperplasia (BPH); Acute pain, Fear, Anxiety, Impaired urinary elimination, deficient Knowledge, Risk for infection, Risk for injury, Sexual dysfunction, Urinary retention Relieve acute urinary retention. Promote comfort. Provide information about disease process, prognosis, and treatment needs. Prevent complications. Help client deal with psychosocial concerns. Sample Nursing care plans for Benign Prostatic Hyperplasia (BPH) with nursing diagnosis Urinary retention (acute or chronic) Patient usually needs assistance with management of therapy and catheter. Provide instructions about all medications used. Provide instructions on the correct dosage, route, action, side effects, and potential drug interactions and when to notify these to the physician, Provide information about specific procedures and tests and what to expect afterward, such as catheter, bloody urine, and bladder irritation · Instruct patients about the need to maintain a high fluid intake, to ensure adequate urine output. · Teach the patient to monitor urinary output for 4 to 6 weeks after surgery to ensure adequacy in volume of elimination combined with a decrease in volume of retention. Teach the patient to recognize the signs of UTI. Urge him to immediately report these signs to the physician because infection can worsen the obstruction. After the catheter is removed, the patient may experience urinary frequency, dribbling and, occasionally, hematuria. Reassure him and family members that he'll gradually regain urinary control Instruct the patient to follow the prescribed oral antibiotic regimen, and tell him the indications for using gentle laxatives. · Provide information about sexual anatomy and function as it relates to prostatic enlargement helps client understand the implications of proposed treatments because they might affect sexual performance. · Encourage the patient to discuss any sexual concerns he or his partner may have after surgery with the appropriate counselors. · Reassure the patient that a session can be set up by the nurse or physician whenever one is indicated. Usually, the physician recommends that the patient have no sexual intercourse or masturbation for several weeks after invasive procedures. Reinforce prescribed limits on activity. Warn the patient against lifting, performing strenuous exercises, and taking long automobile rides for at least 1 month after surgery because these activities increase bleeding tendency. Also caution him not to have sexual intercourse for at least several weeks after discharge Instruct the patient to report any difficulties with urination to the physician immediately. Explain that BPH can recur and that he should notify the physician if symptoms of urgency, frequency, difficulty initiating stream, retention, nocturia, or bladder distension recur. Urge the patient to seek medical care immediately if he can't void at all, if he passes bloody urine, or if develops a fever. Reinforce importance of medical follow-up for at least 6 months to 1 year, including rectal examination and urinalysis. Prepare the patient for diagnostic tests and surgery as appropriate. Obtain a urine culture if UTI is suspected. Administer antibiotics as ordered for UTI, urethral procedures that involve instruments, and cystoscopy. If urine retention occurs, insert an indwelling catheter. Monitor and record the patient’s vital signs, intake, output, and daily weight. Watch closely for signs of postobstructive diuresis such as increased urine output and hypotension, which may lead to serious dehydration, lowered blood volume, shock, electrolyte loses, and anuria. Instruct the patient to follow prescribed oral antibiotics regimen and tell him the indications for using gentle laxatives. Urge the patient to seek medical care immediately if he can’t void, if he passes bloody urine, or if he develops a fever. Advise the patient that it may take several months of medical therapy before symptoms improve. Urge him to seek medical care immediately if he can’t void, if he passes bloody urine, or if he develops fever. Submitted by: Chester Glee Zolina Frances Mariel Ann Espinosa